case_images: PMC10890802_01
case_images: Histology of a gross specimen demonstrating high-grade (FNCLCC grade 3 out of 3) PMRS with a mitotic count of 38 per 10 high power field (HPF); x200 magnification.
case_images: cro-2024-0017-0001-535959_F01.jpg
case_images: PMC10890802_01_cro-2024-0017-0001-535959_F01.jpg
case_images: F1
case_images: Pathology results from this gross specimen demonstrated high-grade (FNCLCC grade 3 of 3) PMRS with a mitotic count of 38 per 10 high power field (Fig. 1).
case_images: Immunohistochemical stain demonstrating negative PD-L1 status; x200 magnification.
case_images: cro-2024-0017-0001-535959_F02.jpg
case_images: PMC10890802_01_cro-2024-0017-0001-535959_F02.jpg
case_images: F2
case_images: PD-L1 testing by immunohistochemistry was negative (Fig. 2).
case_images: Single transverse section of a CT chest scan demonstrating complete response; the patient has no evidence of disease to date.
case_images: cro-2024-0017-0001-535959_F03.jpg
case_images: PMC10890802_01_cro-2024-0017-0001-535959_F03.jpg
case_images: F3
case_images: Repeat CT CAP after cycle 6 of doxorubicin (cycle 5 pembrolizumab) showed complete response in the numerous lung nodules and no evidence of new metastatic disease (Fig. 3).
case_images: PMC10890802_02
case_images: Histology of a gross specimen demonstrating high-grade (FNCLCC grade 3 out of 3) PMRS with a mitotic count of 13 per 10 high power field (HPF); x200 magnification.
case_images: cro-2024-0017-0001-535959_F04.jpg
case_images: PMC10890802_02_cro-2024-0017-0001-535959_F04.jpg
case_images: F4
case_images: Biopsy of the soft tissue mass identified high-grade (FNCLCC grade 3 of 3) PMRS with a mitotic count of 13 per 10 high power field (Fig. 4).
case_images: Immunohistochemical stain demonstrating low-positive PD-L1 status (1+/<25%); x200 magnification.
case_images: cro-2024-0017-0001-535959_F05.jpg
case_images: PMC10890802_02_cro-2024-0017-0001-535959_F05.jpg
case_images: F5
case_images: Of note, tumor testing demonstrated no relevant fusion transcripts, no genetic variants with potential clinical significance, and PD-L1 low-positive (1+/<25%) (Fig. 5).
case_images: Single transverse section of a CT chest scan demonstrating partial response; the previously visualized nodule underwent significant decrease in size.
case_images: cro-2024-0017-0001-535959_F06.jpg
case_images: PMC10890802_02_cro-2024-0017-0001-535959_F06.jpg
case_images: F6
case_images: CT CAP after cycle 3 of doxorubicin (cycle 2 of pembrolizumab) demonstrated an interval decrease in size of the lung metastases consistent with a partial response (Fig. 6).